| Literature DB >> 31692668 |
Sabitu Babatunde Olasupo1, Adamu Uzairu2, Gideon Shallangwa2, Sani Uba2.
Abstract
The norepinephrine transporter (NET) is a Na+/Cl- coupled neurotransmitter transporter responsible for reuptake of released norepinephrine (NE) into nerve terminals in the brain, a key therapeutic used in the treatment of psychiatric disorders. A quantitative structural activity relationship (QSAR) study was performed on 50 compounds of NET inhibitors to investigate their inhibitory potencies against norepinephrine transporter as novel drugs for anti-psychotic disorders. The compounds were optimized by employing Density functional theory (DFT) with basis set of B3LYP/6-31G*. The genetic function Algorithm (GFA) approach was used to generate a highly predictive and statistically significant model with good correlation coefficient R2 Train = 0.952 Cross validated coefficient Q2 cv = 0.870 and adjusted squared correlation coefficient R2 adj = 0.898. The predictability and accuracy of the developed model was evaluated through external validation using test set compound, Y-randomization and applicability domain techniques. The results of Molecular docking analysis by using two neurotransmitter transporters PDB ID 2A65 (resolution = 1.65 Å) and PDB ID 4M48 (resolution = 2.955 Å) showed that two of the ligands (compound 12 and 44) having higher binding affinity were observed to inhibit the targets by forming hydrogen bonds and hydrophobic interactions with amino acids of the two receptors respectively. The results of these studies would provide important new insight into the molecular basis and structural requirements to design more potent and more specific therapeutic anti-psychotic drugs/agents.Entities:
Keywords: Antipsychotic; Density functional theory; Drug; Genetic function approximation; Norepinephrine transporter; Pharmaceutical chemistry; QSAR
Year: 2019 PMID: 31692668 PMCID: PMC6806411 DOI: 10.1016/j.heliyon.2019.e02640
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Fig. 1Prepared structures of the targets.
Descriptive statistical analysis of NET inhibitor compounds.
| Descriptive values | Training dataset | Test dataset |
|---|---|---|
| Dataset Number | 36 | 14 |
| Standard Error | 0.185 | 0.296 |
| Median | 7.054 | 7.497 |
| Standard Deviation | 1.108 | 1.106 |
| Sample Variance | 1.227 | 1.223 |
| Kurtosis | -0.632 | 2.677 |
| Skewness | 0.229 | -1.264 |
| Range | 4.439 | 4.436 |
| Minimum | 5.084 | 4.500 |
| Maximum | 9.523 | 8.936 |
| Mean | 6.940 | 7.394 |
Names of the model descriptors and their respective degree of contribution.
| Descriptor | Descriptor Name | Type | Degree of contribution | percentage of contribution |
|---|---|---|---|---|
| ALogP | Ghose-Crippen LogKow | 2D | 0.513 | 13.3 |
| AATS7i | Average Broto-Moreau autocorrelation - lag 7/weighted by first ionization potential | 2D | 0.500 | 13.0 |
| ATSC3p | Centered Broto-Moreau autocorrelation - lag 3/weighted by polarizabilities | 2D | 0.631 | 16.4 |
| IC2 | Information content index (neighborhood symmetry of 2-order) | 2D | 0.383 | 10.0 |
| GGI10 | Topological charge index of order 10 | 2D | -1.061 | 27.6 |
| RDF75u | Radial distribution function - 075/unweighted | 3D | 0.756 | 19.7 |
Accepted QSAR model validation tools [21].
| Validation Tools | Interpretation | Acceptable Value | Developed model Value | Remarks |
|---|---|---|---|---|
| R2 | Co-efficient of determination | ≥0.6 | 0.911 | pass |
| P(95%) | Confidence interval at 95% confidence level | <0.05 | 2.446 | pass |
| Q2cv | Cross-Validation Co-efficient | >0.5 | 0.870 | pass |
| R2-Q2cv | Difference between R2 and Q | ≤0.3 | 0.04 | pass |
| N Ext testset | Minimum number of external and test sets | ≥5 | 14 | pass |
| R2Testset | Co-efficient of determination of external and test set | ≥0.5 | 0.5850 | pass |
| cR2p | Coefficient of determination for | >0.5 | 0.840 | pass |
| R2adj | Adjusted R-squared | >0.6 | 0.893 | Pass |
| VIF | Variance Inflation Factor | <10 | 1.4–4.4 | Pass |
| t-test | t-Statistice value | >2 | 5–9 | Pass |
Pearson's correlation matrix and model quality assurance.
| VIF | t-statistics | p value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ALogP | 1 | 1.5021 | 7.5604 | 2.47E08 | |||||
| AATS7i | -0.3321 | 1 | 1.4789 | 7.4649 | 3.16E-08 | ||||
| ATSC3p | -0.2592 | -0.2991 | 1 | 1.4376 | 9.4970 | 2.1E-10 | |||
| IC2 | -0.2742 | 0.0487 | 0.0765 | 1 | 1.4177 | 5.8502 | 2.4E-06 | ||
| GGI10 | -0.2382 | 0.0921 | -0.1711 | 0.5005 | 1 | 4.5022 | -9.5663 | 1.79E-10 | |
| RDF75u | -0.2940 | 0.2215 | -0.1337 | 0.4759 | 0.6377 | 1 | 4.3800 | 6.7912 | 1.87E-07 |
Fig. 2Plot of predicted pKi values against experimental pKi values for training and test sets.
Fig. 3A Williams plot for the data set of pKi standardized residual against its descriptor space.
Fig. 4Plot of predicted pKi values against experimental pKi values for training.
Y-randomization table for QSAR Analysis.
| Model | R | Rˆ2 | Qˆ2 |
|---|---|---|---|
| Original | 0.9545 | 0.9111 | 0.8702 |
| Random 1 | 0.4197 | 0.1762 | -0.2759 |
| Random 2 | 0.3402 | 0.1157 | -0.4558 |
| Random 3 | 0.3943 | 0.1555 | -0.3333 |
| Random 4 | 0.4690 | 0.2199 | -0.2220 |
| Random 5 | 0.4408 | 0.1943 | -0.1861 |
| Random 6 | 0.1560 | 0.0243 | -0.6456 |
| Random 7 | 0.3589 | 0.1288 | -0.3166 |
| Random 8 | 0.3237 | 0.1048 | -0.3536 |
| Random 9 | 0.3323 | 0.1104 | -0.4357 |
| Random 10 | 0.3646 | 0.1329 | -0.3307 |
| Random Models Parameters | |||
| Average r: | 0.3599 | ||
| Average rˆ2: | 0.1363 | ||
| Average Qˆ2: | -0.3555 | ||
| cRpˆ2: | 0.8439 |
Fig. 5(12a 2D&3D), (38a 2D&3D) and (44a 2D&3D) depict 2D and 3D interactions at the binding site between receptor PDB code 2A65 with ligand 12, 38 and 44 while (12m 2D&3D), (38m 2D&3D) and (44m 2D&3D) show 2D and 3D interactions at the binding site between receptor PDB code 4M48 with ligand 12, 38 and 44 respectively.
Molecular interactions between the three ligands of higher binding affinity and the two receptors.
| Ligand CHEMBL ID | Ligand Number | Binding Affinity (kcal/mol) | Hydrogen bond | Hydrophobic interactions | Electrostatics Interactions | |
|---|---|---|---|---|---|---|
| Amino acid | Bond length (Å) | Amino Acid | Amino Acid | |||
| CHEMBL67078 | 12a | -9.3 | LYS398 | 2.15279 | ILE111, ALA319, VAL154, LEU162, LEU400, LEU25 | |
| 12m | -7.35 | SER31 | 2.76717 | PHE513,TYR32 | TYR32 | |
| SER31 | 2.31044 | |||||
| CHEMBL197384 | 38a | -10.3 | ILE491, ILE410, TRP406,TRP99, PHE494,ARG487,LEU464.ALA464,ILE472 | PHE414 | ||
| 38m | -7.5 | ASP25 | 2.53334 | TYR337, TYR59, ARG92 | ASP25 | |
| CHEMBL200310 | 44a | -9.9 | GLN34 | 2.62533 | ILE475, TYR471, ILE245, LYS474,ARG30,ALA319 | ASP404 |
| 44m | -8.45 | PRO514 | 2.15327 | PHE513, VAL101 | ||
| SER31 | 2.76554 | |||||
| TRP519 | 2.1523 | |||||